Shareholders alerted by Bernstein Litowitz Berger & Grossmann LLP about the …

Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP has initiated a securities class action lawsuit against Corcept Therapeutics Incorporated and certain senior executives, alleging violations of federal securities laws. This legal action is on behalf of investors who bought or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, known as the Class Period, in the U.S. District Court for the Northern District of California. The case, titled Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), is the result of a comprehensive investigation and thorough assessment of the case’s merits.

Corcept Therapeutics is a pharmaceutical company specializing in developing medications for severe endocrinologic, oncologic, metabolic, and neurologic conditions by altering cortisol hormone effects. One of its key products under development is relacorilant, intended for various medical uses, including treating hypercortisolism, also known as Cushing’s syndrome. Throughout the Class Period, Defendants allegedly claimed that crucial clinical trials supporting relacorilant’s use for hypercortisolism treatment provided robust backing for the New Drug Application submitted to the U.S. Food and Drug Administration (FDA) for approval. They also assured stakeholders that discussions with the FDA regarding this application had been positive and that they were optimistic about the approval process. Towards the end of the Class Period, the Defendants maintained that relacorilant was on the brink of approval. However, contrary to these assurances, the FDA had expressed multiple concerns regarding the adequacy of clinical data supporting the relacorilant NDA, casting doubts on its approval.

The lawsuit alleges that the Defendants released misleading statements regarding the status and prospects of relacorilant’s FDA approval, causing investors to trade Corcept stock at artificially inflated prices. The false and misleading statements inflated the share value, leading to financial losses for investors who acted based on this inaccurate information. The complaint further states that during the Class Period, Corcept’s senior management overstated the likelihood of relacorilant’s fast-track approval by the FDA, concealing the potential risks associated with the drug’s approval process. As a result, investors faced financial harm due to misinformation provided by Corcept Therapeutics and its senior executives.

The complaint underlines the necessity of integrity and transparency in the pharmaceutical sector to protect investors and stakeholders from misleading information that could significantly impact their financial decisions. The importance of stringent regulatory oversight and ethical conduct by pharmaceutical companies is emphasized to maintain public trust and safeguard investor interests in the industry. Undoubtedly, legal actions like this lawsuit play a crucial role in holding companies accountable for their actions, promoting transparency, and protecting investors from financial harm resulting from deceptive practices.